Cancer incidence and development have a direct causative association with pathogenic bacteria. Pathogen targeting is a unique cancer treatment strategy aimed at reversing the established microorganism imbalance. In vivo and in vitro studies have shown that some pathogenic bacteria can promote tumor progression and cause chemotherapy resistance. Therefore, selectively targeted microbial therapy may inhibit cancer migration and change chemotherapy resistance to benefit cancer patients. Furthermore, natural compounds are valuable sources for antibacterial medication development. To change tumor chemotherapy resistance caused by pathogenic bacteria, multiple drug resistance of tumors, rare tumors, and other clinically unmet needs, natural products (antibacterial peptides, small molecule compounds, polysaccharides, and other natural products as well as clinical drugs) and novel targeted therapies such as peptide drug conjugate (PDC) and small molecule-drug conjugate (SMDC) are clinically unmet needs that can benefit the majority of tumor patients.
This Research Topic aims to present the advance of cancer therapy targeting pathogenic bacteria and developing probiotics, such as small molecule compounds, antimicrobial peptides, polysaccharides, and other natural products as well as clinical drugs, to improve cancer treatment effects and reverse chemotherapy resistance or inhibit the cancer migration caused by pathogenic bacteria, tumor multidrug resistance, etc. We welcome submissions of original studies, short communications, and review articles on carcinogenesis, cancer migration, and chemotherapy resistance caused by gastrointestinal tumor-related pathogenic bacteria and developing natural products targeting pathogenic bacteria. In particular, we encourage the novel discovery of probiotics that target pathogens.
This Research Topic welcomes original research, reviews, and meta-analysis articles. The directions include but are not limited to the following:
1. Carcinogenesis, cancer migration, and chemotherapy resistance caused by gastrointestinal tumor-related pathogenic bacteria.
2. Targeting gastrointestinal tumor-related pathogenic bacteria to screen, design, and develop novel drugs of natural products.
3. Development of probiotics (antibacterial peptides, small molecule compounds, polysaccharides, and other natural products as well as clinical drugs) targeting carcinogenic pathways of pathogenic bacteria.
4. Probiotics targeted therapy for pathogenic bacteria through synthetic biology and other methods to improve cancer treatment effects.
5. The development of novel drugs targeting pathogenic bacteria by organoid or intestinal chip technology to improve anti-cancer effects.
Cancer incidence and development have a direct causative association with pathogenic bacteria. Pathogen targeting is a unique cancer treatment strategy aimed at reversing the established microorganism imbalance. In vivo and in vitro studies have shown that some pathogenic bacteria can promote tumor progression and cause chemotherapy resistance. Therefore, selectively targeted microbial therapy may inhibit cancer migration and change chemotherapy resistance to benefit cancer patients. Furthermore, natural compounds are valuable sources for antibacterial medication development. To change tumor chemotherapy resistance caused by pathogenic bacteria, multiple drug resistance of tumors, rare tumors, and other clinically unmet needs, natural products (antibacterial peptides, small molecule compounds, polysaccharides, and other natural products as well as clinical drugs) and novel targeted therapies such as peptide drug conjugate (PDC) and small molecule-drug conjugate (SMDC) are clinically unmet needs that can benefit the majority of tumor patients.
This Research Topic aims to present the advance of cancer therapy targeting pathogenic bacteria and developing probiotics, such as small molecule compounds, antimicrobial peptides, polysaccharides, and other natural products as well as clinical drugs, to improve cancer treatment effects and reverse chemotherapy resistance or inhibit the cancer migration caused by pathogenic bacteria, tumor multidrug resistance, etc. We welcome submissions of original studies, short communications, and review articles on carcinogenesis, cancer migration, and chemotherapy resistance caused by gastrointestinal tumor-related pathogenic bacteria and developing natural products targeting pathogenic bacteria. In particular, we encourage the novel discovery of probiotics that target pathogens.
This Research Topic welcomes original research, reviews, and meta-analysis articles. The directions include but are not limited to the following:
1. Carcinogenesis, cancer migration, and chemotherapy resistance caused by gastrointestinal tumor-related pathogenic bacteria.
2. Targeting gastrointestinal tumor-related pathogenic bacteria to screen, design, and develop novel drugs of natural products.
3. Development of probiotics (antibacterial peptides, small molecule compounds, polysaccharides, and other natural products as well as clinical drugs) targeting carcinogenic pathways of pathogenic bacteria.
4. Probiotics targeted therapy for pathogenic bacteria through synthetic biology and other methods to improve cancer treatment effects.
5. The development of novel drugs targeting pathogenic bacteria by organoid or intestinal chip technology to improve anti-cancer effects.
